Home » Newsletters » BioWorld Science

BioWorld Science

April 26, 2005

View Archived Issues

Similar analgesic effects found for M6G and morphine sulfate after major surgery

Rimonabant reduces the prevalence of metabolic syndrome among obese patients

Researchers find a lower incidence of AMD in subjects taking cholesterol-lowering drugs

Protective effects of STAZN following hemorrhagic shock

PRO-001 a novel therapeutic strategy for multiple myeloma

Myocardial protective properties of H-89

Baraclude available in U.S.

AEterna Zentaris establishes collaboration with Julius Maximilians University

Positive findings for low-dose doxepin in elderly patients with insomnia

Series C financing to advance Molecular Insight's BMIPP into phase III

AFG-495, a cathepsin K inhibitor, evaluated for bone metastases

Thalidomide analogues show antiangiogenic actions in vitro

Titanocene derivative tested for anticancer activity

EP-1572 reported to induce growth hormone secretion in healthy volunteers

Update on the effects and safety of DAC:GLP-1 in type 2 diabetes

EMEA completes review of antidepressants in children and adolescents

KOS-1584 shows promise as a novel antitumor drug

First evidence for the benefits of statin therapy in PCOS

New formulations of dapsone for cerebral infarction

Recent patents cover novel therapeutic agents for vascular disorders

CHMP recommends lifting marketing restrictions on Serdolect

Provensis plans to submit study protocol for Varisolve

Risperdal approved in Canada for acute treatment of manic symptoms

Bar-Ilan University describes therapeutic agents for use in male contraception

Kyorin to acquire Toyo Pharmar stock

Prodrugs for treating alcoholism and opioid dependency developed at the University of Kentucky

Dual-targeting estrone sulfatase inhibitor/SERM for breast cancer therapy

New agents for thrombocytopenia from Yamanouchi R&D

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 18, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for June 18, 2025.
An early stage 85% remissions rate in AML drives Aptevo’s stock surge
BioWorld
An 85% remissions rate was found in updated results from Aptevo Therapeutics Inc.’s ongoing phase Ib/II Ranier study of mipletamig in one of the toughest blood...
BIO 2025: Makary lays out FDA’s path, launches pilot review program
BioWorld
On the same day that FDA Commissioner Martin Makary spoke in a fireside chat during the 2025 Biotechnology Innovation Organization’s International Convention, the...
Alphadesign: AI creating proteins from scratch
BioWorld Science
The Alphafold machine learning system for predicting a protein’s structure from its amino acid sequence has been adapted to make it possible to design de novo...